GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
80.47
-1.22 (-1.49%)
At close: Jul 16, 2025, 4:00 PM
81.82
+1.35 (1.68%)
After-hours: Jul 16, 2025, 7:59 PM EDT
GeneDx Holdings Employees
GeneDx Holdings had 1,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$330,143
Profits / Employee
-$38,576
Market Cap
2.30B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,000 | 0 | - |
| Dec 31, 2023 | 1,000 | -100 | -9.09% |
| Dec 31, 2022 | 1,100 | -100 | -8.33% |
| Dec 31, 2021 | 1,200 | 328 | 37.61% |
| Dec 31, 2020 | 872 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
WGS News
- 1 day ago - GeneDx: Strong Testing Volume And An Invaluable Genomic Database - Seeking Alpha
- 6 days ago - GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025 - Business Wire
- 21 days ago - GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics - Business Wire
- 23 days ago - GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability - Business Wire
- 4 weeks ago - WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 7 weeks ago - GeneDx to Participate in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale - Business Wire
- 2 months ago - GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip - Seeking Alpha